Deals In Depth: October 2022

There were two $1bn+ deals signed in October. Topping the list was a potential $1.76bn deal between Jazz Pharmaceuticals plc and Zymeworks, Inc. in which Jazz acquires development and commercialization rights to Zymeworks' zanidatamab across all indications in the US, Europe, Japan and all other territories except for those Asia/Pacific territories previously out-licensed by Zymeworks. Zymeworks is eligible to receive a $50m up-front payment, and should Jazz decide to continue the collaboration following readout of the top-line clinical data from HERIZON-BTC-01, a second one-time payment of $325m. Zymeworks is also eligible to receive up to $525m upon the achievement of certain regulatory milestones and up to $862.5m in potential commercial milestone payments. (Also see "Zymeworks Deal Expands Jazz’s Potential Oncology Presence" - Scrip, 19 October, 2022.)

In the top October M&A by deal value, Thermo Fisher Scientific entered into a definitive agreement to acquire privately...